Latest News About COVID-19 Off-Label Treatments
California’s Medical ‘Misinformation’ Crusade Could Cost Lives says Wall Street Journal
Throughout history, many advances in medical care have been discovered as a result of physician’s rights to employ clinical experience, personal knowledge, and scientific evidence in their practice. A new proposed legislation in California stands to restrict this right.
University of Virginia Medical Center Joins National Study Analyzing COVID-19 Treatments
UVA Health joins the ACTIV-6 study, sponsored by the National Institute of Health, in pursuit for better therapeutic options for their mild COVID-19 patients. The ACTIV-6 study is investigating the efficacy of fluvoxamine and ivermectin for COVID-19.
‘Patients Are Frustrated’: Long COVID Poses Bumpy Road to Recovery
Experts at Staten Island University Hospital speak about the prevalence and presentation of long-COVID. Researchers are interested in testing whether the positive impact of the anti-ulcer drug famotidine on COVID-19 recovery rate leads to a reduced risk for long COVID.
New US clinical trial shows benefits of Pepcid for treating mild to moderate COVID-19
Clinical trial results, published in the British Medical Journal Gut, demonstrate that the anti-ulcer drug famotidine (also known as Pepcid), leads to faster COVID-19 symptom recovery in patients diagnosed with mild to moderate COVID-19.